GlassScriptPhysician profile
Harshit M Patel
NPI 1467453571
$9,114.60
in general payments reported to CMS, 2019-2025
36 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $677 · 2021: $1,062 · 2022: $1,388 · 2023: $1,411 · 2024: $1,734 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,901 · Education: $56.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,901.04 |
| Education | $56.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,984.42 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,458.00 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,117.33 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $756.38 | 2019-2024 | |
| Optinose US, INC. | $504.01 | 2019-2025 | |
| Amgen INC. | $460.33 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $418.42 | 2019-2025 | |
| Csl Behring | $335.06 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Biocryst US Sales Co., LLC | $287.76 | 2021-2023 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.59 | 2021-2024 | Takhzyro, Eohilia |
| Ars Pharmaceuticals Operations, INC. | $161.73 | 2025 | Neffy |
| Pharming Healthcare, INC. | $161.32 | 2019-2023 | Ruconest |
| Genentech USA, INC. | $152.90 | 2019-2025 | Xolair |
| Blueprint Medicines Corporation | $138.06 | 2022-2024 | Ayvakit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.65 | 2021-2025 | |
| Grifols USA, LLC | $80.13 | 2022-2025 | Xembify |
| Kaleo, INC. | $69.21 | 2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $65.81 | 2019-2023 | |
| Phadia US INC. | $62.83 | 2022-2024 | Immunocap |
| Incyte Corporation | $48.48 | 2021-2022 | |
| Shire North American Group INC | $44.71 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $35.38 | 2020 | |
| Ionis Pharmaceuticals, INC. | $31.62 | 2025 | |
| Alk-Abello, INC | $30.33 | 2019-2024 | Odactra, Ragwitek, Grastek |
| Horizon Therapeutics Plc | $28.00 | 2019-2021 | |
| Covis Pharma Gmbh | $25.93 | 2020 | |
| Aimmune Therapeutics, INC. | $25.31 | 2021 | |
| Lilly USA, LLC | $24.20 | 2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $21.23 | 2021 | |
| Galderma Laboratories, L.P. | $21.12 | 2025 | Nemluvio |
| Eyevance Pharmaceuticals LLC | $19.16 | 2021 | |
| Tersera Therapeutics LLC | $18.56 | 2025 | Quzyttir |
| Mdd US Operations, LLC | $18.29 | 2020 | |
| Uswm, LLC | $16.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harshit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.